JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46

Benzinga Newsdesk www.benzinga.com Neutral 55.5%

Neg 0% Neu 55.5% Pos 0%

JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and announces Price Target of $46.